Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Bebtelovimab/Sotrovimab

Emergence of drug resistance following off label use

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Marques AD, et al. SARS-CoV-2 evolution during prolonged infection in immunocompromised patients. mBio 15: e0011024, No. 3, Mar 2024. Available from: URL: https://dx.doi.org/10.1128/mbio.00110-24 Marques AD, et al. SARS-CoV-2 evolution during prolonged infection in immunocompromised patients. mBio 15: e0011024, No. 3, Mar 2024. Available from: URL: https://dx.doi.org/10.1128/mbio.00110-24
Metadaten
Titel
Bebtelovimab/Sotrovimab
Emergence of drug resistance following off label use
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-55468-x

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Amphotericin-B